有机化学人才网 | 最新人才 | 最新职位 | 技术交易 | 药物合成 |
   
全站搜索: |
  您当前位置:网站首页 >> 药物合成路线图解
 

药物详细合成路线

Name Ruprintrivir;AG-7088
Chemical Name 4(S)-[2(R)-(4-Fluorobenzyl)-6-methyl-5(S)-(5-methylisoxazol-3-ylcarboxamido)-4-oxoheptanamido]-5-[2-oxo-3(S)-pyrrolidinyl]-2(E)-pentenoic acid ethyl ester
CAS 223537-30-2
Related CAS
Formula C31H39FN4O7
Structure
Formula Weight 598.67748
Stage II 期临床
Company Agouron (Originator)
Activity/Mechanism ANTIINFECTIVE THERAPY, Anti-Rhinovirus Drugs, Antiviral Drugs, HRV 3C Protease Inhibitors
Syn. Route 4
Route 1
tetrahydrofuranone (xiii): the grignard condensation of isobutyraldehyde (i) with vinylmagnesium bromide (ii) in thf gives the magnesium alcoholate (iii), which is condensed with ethyl malonyl chloride (iv) in the same solvent, yielding the mixed ester (v). treatment of (v) with ti(oet)4 at 190 c affords 6-methyl-4(e)-heptenoic acid methyl ester (vi), which by reaction with (r,r)-(-)-pseudoephedrine (vii), oxalyl chloride and dmf in benzene gives the amide (viii). the regiocontrolled addition of 4-fluorobenzyl chloride (ix) to the chiral amide (viii) by means of buli and licl in thf yields the 2(s)-(4-fluorobenzyl)heptanamide (x), which by reaction with nbs in thf/water/acetic acid at 0 c, followed by reflux for 45 min, affords 5(s)-[1(r)-bromo-2-methylpropyl]-3(r)-(4-fluorobenzyl)tetrahydrofuran-2-one (xi). the reaction of (xi) with nan3 in dmf gives the corresponding azide (xii), which is reduced with h2 over pd/c, and the resulting amine is protected with tert-butoxycarbonyl anhydride to obtain the desired tetrahydrofuranone (xiii).
List of intermediates No.
tert-butyl 4-[(4r,7s,10s,13r,16s,19r)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-4-([[(4r,5r)-2-(4-[2-[(hydroperoxymethyl)amino]-2-oxoethoxy]phenyl)-4-methyl-1,3-dioxan-5-yl]amino]carbonyl)-16-(4-hydroxybenzyl)-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3 (iv)
tert-butyl [(3r,4s)-1-benzyl-4-(trifluoromethyl)pyrrolidinyl]methylcarbamate (i)
benzhydryl (6r,7r)-7-[((2r,3s)-2-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-3-hydroxybutanoyl)amino]-3-[[(1-methyl-1h-1,2,3,4-tetraazol-5-yl)sulfanyl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate (ii)
ethyl 4-(2-formyl-6-methoxyphenoxy)-3-nitrobenzoate (ix)
2-bromo-1-phenyl-1-ethanone (iii)
2-[(3,4-dimethoxyphenethyl)(methyl)amino]-1-phenyl-1-ethanone (v)
2-[(3,4-dimethoxyphenethyl)(methyl)amino]-1-phenyl-1-ethanol (vi)
2-(5-oxo-2-pyrrolidinyl)acetonitrile (viii)
5-[2-(dimethylamino)ethyl]-2-pyrrolidinone (x)
dimethyl[2-(5-oxo-2-pyrrolidinyl)ethyl]ammoniumolate (xi)
5-vinyl-2-pyrrolidinol (xii)
1-[(e)-1-butenyl]-5-vinyl-2-pyrrolidinone (xiii)
1-naphthoic acid (vii)
Reference 1:
    worland, s.t.; ferre, r.a.; patick, a.k.; prins, t.j.; meador, j.w. iii; zhou, r.; dragovich, p.s.; fuhrman, s.a.; matthews, d.a.; ford, c.e.; structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3c protease inhibitors. 3. structure-activity studies of ketomethylene-containing peptidomimetics. j med chem 1999, 42, 7, 1203.
Reference 2:
    graul, a.; casta?er, j.; ag-7088. drugs fut 2000, 25, 1, 9.
Reference 3:
    meyer, m.d.; daanen, j.f.; ehrlich, p.p.; ralston, j.w. (abbott laboratories inc.); 3-phenylpyrrole alpha-1 adrenergic cpds.. wo 9957122 .

Route 2
pyrrolidinone (xxvi): the selective hydrolysis of the known methyl ester (xiv) with naoh in methanol/water gives the corresponding carboxylic acid (xv), which is coupled with the chiral oxazolidinone (xvi) by means of pivaloyl chloride and et3n in thf to yield the amide (xvii). the regiocontrolled alkylation of (xvii) with allyl iodide and nan(sime3)2 in thf affords the allyl derivative (xviii), which is submitted to ozonolysis in dichloromethane to provide the aldehyde (xix). the condensation of (xix) with 2,4-dimethoxybenzylamine (xx) yields imine (xxi), which by a reductive cyclization with nabh3cn in thf/etoh affords pyrrolidinone (xxii). cleavage of the oxazolidine ring of (xxii) with tsoh in hot methanol gives the amino alcohol (xxiii), which is oxidized with oxalyl chloride in dmso to the aldehyde (xxiv). finally, this compound is condensed with triethyl phosphonoacetate (xxv) by means of nan(sime3)2 in thf to provide the desired pyrrolidinone (xxvi).
List of intermediates No.
methyl (1r,2r)-1-hydroxy-7-methoxy-1,2,3,4-tetrahydro-2-naphthalenylcarbamate (xxv)
(3as,4r,8r,8as)-4,8-dibenzyl-2,2-dimethylhexahydro-6h-[1,3]dioxolo[4,5-e][1,3]diazepin-6-one (xvi)
n-methyl-1-naphthamide (xxvi)
1,3-benzodioxole-5-carbaldehyde (xiv)
(e)-1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-one (xv)
1-chloro-3-(2-nitro-1h-imidazol-1-yl)-2-propanol (xvii)
2-nitro-1-(2-oxiranylmethyl)-1h-imidazole
4-methylbenzaldehyde (xviii)
(6-bromo-2-pyridinyl)(4-methylphenyl)methanol (xix)
(6-bromo-2-pyridinyl)(4-methylphenyl)methanone (xx)
ethyl (e)-3-[6-(4-methylbenzoyl)-2-pyridinyl]-2-propenoate (xxi)
ethyl (e)-3-[6-[(e)-1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2-pyridinyl]-2-propenoate (xxii)
methyl 4-((2r)-2-[[(2r)-2-hydroxy-2-phenylethyl]amino]propyl)benzoate (xxiii)
methyl 4-cyanobenzoate (xxiv)
Reference 1:
    dragovich, p.s.; prins, t.j.; zhou, r.; et al.; structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3c protease inhibitors. 4. incorporation of p1 lactam moieties as l-glutamine replacements. j med chem 1999, 42, 7, 1213.
Reference 2:
    graul, a.; casta?er, j.; ag-7088. drugs fut 2000, 25, 1, 9.
Reference 3:
    meyer, m.d.; daanen, j.f.; ehrlich, p.p.; ralston, j.w. (abbott laboratories inc.); 3-phenylpyrrole alpha-1 adrenergic cpds.. wo 9957122 .

Route 3
final coupling: deprotection of (xxvi) with hcl in dioxane followed by condensation with tetrahydrofuranone (xiii) by means of diea in dmf gives the amide (xxvii). this compound is also deprotected with hcl as before and condensed with 5-methylisoxazol-3-ylcarbonyl chloride (xviii) by means of pyridine to afford the protected compound (xxix), which is finally treated with ddq, yielding ag-7088.
List of intermediates No.
1-[(e)-1-butenyl]-5-vinyl-2-pyrrolidinone (xiii)
n-methyl-1-naphthamide (xxvi)
n-methyl(1-naphthyl)methanamine; n-methyl-n-(1-naphthylmethyl)amine (xxvii)
1,3-benzodioxole-5-carboxylic acid (xxviii)
1,3-benzodioxol-5-ylmethanol (xxix)
Reference 1:
    dragovich, p.s.; prins, t.j.; zhou, r.; et al.; structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3c protease inhibitors. 4. incorporation of p1 lactam moieties as l-glutamine replacements. j med chem 1999, 42, 7, 1213.
Reference 2:
    worland, s.t.; ferre, r.a.; patick, a.k.; prins, t.j.; meador, j.w. iii; zhou, r.; dragovich, p.s.; fuhrman, s.a.; matthews, d.a.; ford, c.e.; structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3c protease inhibitors. 3. structure-activity studies of ketomethylene-containing peptidomimetics. j med chem 1999, 42, 7, 1203.
Reference 3:
    graul, a.; casta?er, j.; ag-7088. drugs fut 2000, 25, 1, 9.

Route 4
the alkylation of dimethyl l-glutamate (i) with 2-bromoacetonitrile (ii) by means of lihmds in thf gives stereoselectively the cyanomethyl derivative (iii), which is reduced with h2 over pto2 in methanol/chcl3 to yield the corresponding 2-aminoethyl derivative (iv). the cyclization of (iv) by means of na2co3 in the same solvent affords the pyrrolidinone (v), whose ester group is reduced with nabh4 in methanol/thf to provide the propanol derivative (vi). the oxidation of (vi) with so3/pyridine and diea in dmso/dichloromethane gives the aldehyde (vii), which is finally condensed with ethyl 2-bromoacetate (viii) by means of et3p in dichloromethane to yield the chiral 4-(tert-butoxycarbonyl)-5-(2-oxopyrrolidin-3-yl)-2-pentanoic acid ethyl ester (ix), the desired target key intermediate.
List of intermediates No.
[(2r,3s,4s,5r)-5-(6-amino-2-fluoro-9h-purin-9-yl)-3,4-dihydroxytetrahydro-2-furanyl]methyl diethyl phosphate (viii)
7-amino-1,3-benzoxazol-2(3h)-one (ii)
Reference 1:
    tian, q.; et al.; an efficient synthesis of a key intermediate for the preparation of the rhinovirus protease inhibitor ag7088 via asymmetric dianionic cyanomethylation of n-boc-l-(+)-glutamic acid dimethyl ester. tetrahedron lett 2001, 42, 39, 6807.

来源:药化网

作者:药化小编

摘要:本文合成路线介绍的是药物中文名芦平曲韦;英文名Ruprintrivir;AG-7088;CAS[223537-30-2]

 
推荐VIP企业
无锡景耀生物科技有限公司
杭州卢普生物科技有限公司
宁波赛伦化工有限公司
苏州昊赛生物科技有限公司
北京嘉盛扬医药科技有限公司
上海泽涵生物医药科技有限公司
河北固安三利化工公司
郑州凯普瑞生物技术有限公司
上海药谷药业有限公司
兰州康寓信生物科技有限公司
湖北朗昕生化药业有限公司
武汉福鑫化工有限公司
嘉兴市英南化工有限公司
苏州迪飞医药科技有限公司
唐山盛源泽兴化工有限公司
上海盛中医药化工有限公司
连云港天和化学有限公司
南京晨瑞医药科技有限公司
南京苏如化工有限公司
常州瑞盛化工有限公司
热门文章
卢森堡将自2021年起禁止草甘
我国自主开发的首个植物生长调节
2019年中国农业科学10大重
回顾中国农药发展历程,思考行业
巴斯夫:到2030年在巴西推出
辉丰股份拟申请市级复产复核,原
浅析2019年农药登记情况及未
国内最大二甲戊灵原药生产企业—
诺普信战略投资云南华云金鑫,聚
UPL拟收购乐亭永乐100%股
销售额超5亿美元的最年轻品种,
17种铜制剂在我国的登记作物范
“ST丰山”变更为“丰山集团”
第十二届Agrow Award
国家农业最新补贴政策,不要错过
极具潜力的除草剂——吡氟酰草胺
国内乳腺癌潜力市场,第2款CD
走专精特新之路,打造隐形冠军—
苏利股份氟啶胺原药获得巴西登记
国务院:原研药/一致性仿制药,
 友情链接
有机化学人才网  
首页 | 广告服务 | 建站服务 | 关于我们 | 联系我们 | 版权声明